Key Points
- CEO Daniel O’Day sold 15,000 Gilead shares for approximately $2.22 million at an average price of $147.90, reducing his holdings by 2.58% to 566,683 shares. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year, and exceeded analysts’ EPS expectations. Its quarterly dividend is $0.82 per share, equivalent to a $3.28 annualized payout and a 2.3% yield.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $158.78; institutional investors own approximately 83.67% of the company.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel O'Day sold 15,000 shares of the company's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the completion of the sale, the chief executive officer owned 566,683 shares of the company's stock, valued at approximately $83,812,415.70. This trade represents a 2.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Patrick O'day also recently made the following trade(s):
- On Tuesday, September 1st, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $148.64, for a total transaction of $2,229,600.00.
- On Monday, August 3rd, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00.
Gilead Sciences Price Performance
Shares of GILD opened at $144.74 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. Gilead Sciences, Inc. has a fifty-two week low of $109.66 and a fifty-two week high of $157.29. The firm has a 50-day simple moving average of $143.63 and a 200-day simple moving average of $136.55. The company has a market capitalization of $179.47 billion, a price-to-earnings ratio of -54.21 and a beta of 0.31.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.01 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.48 earnings per share for the current year.
Gilead Sciences Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were issued a $0.82 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. Gilead Sciences's payout ratio is presently -122.85%.
Wall Street Analyst Weigh In
GILD has been the subject of several recent research reports. HSBC increased their price target on Gilead Sciences from $155.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, September 10th. Cantor Fitzgerald reissued an "overweight" rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a "sector perform" rating in a research report on Wednesday, August 5th. Wall Street Zen upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research note on Saturday, September 19th. Finally, Truist Financial dropped their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a research note on Tuesday, July 7th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $158.78.
Get Our Latest Analysis on Gilead Sciences
Institutional Investors Weigh In On Gilead Sciences
Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. Legal & General Group Plc acquired a new position in shares of Gilead Sciences during the second quarter valued at $1,316,606,000. Deutsche Bank AG bought a new stake in shares of Gilead Sciences during the second quarter valued at about $918,387,000. Boston Partners bought a new stake in shares of Gilead Sciences during the fourth quarter valued at about $517,808,000. Finally, Jupiter Topco LLC acquired a new stake in Gilead Sciences in the second quarter worth about $448,021,000. Institutional investors and hedge funds own 83.67% of the company's stock.
Gilead Sciences News Roundup
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead’s HIV portfolio remains the primary growth driver. Biktarvy helped lift quarterly revenue to approximately $7.8 billion, while the company’s broader revenue increased 10.6% year over year. Biktarvy Drives Gilead Sciences Revenue to $7.8 Billion
- Positive Sentiment: Barron’s reiterated a bullish view, noting that Gilead shares have risen 35% since its earlier coverage but arguing that the company’s catalysts have not yet fully played out. The view supports continued investor interest in the pipeline and core HIV business. More Upside Awaits for Gilead Sciences Stock
- Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth about $2.2 million. Because the transaction was executed under a pre-arranged Rule 10b5-1 plan, it may have limited bearish significance, although insider selling can weigh on sentiment. Gilead SEC Form 4 Filing
- Neutral Sentiment: Gilead has become one of the most-watched stocks among Zacks users, indicating elevated market attention but not necessarily a change in fundamentals. Gilead Trending Stock Analysis
- Negative Sentiment: Zacks Research downgraded Gilead from “strong buy” to “hold,” potentially encouraging profit-taking after the stock’s strong recent advance and reducing near-term buying support.
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.
Gilead's portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
